Diego Díaz García: Using ctDNA to Track Resistance in Metastatic NSCLC
Diego Díaz García, Medical Oncologist / CEO / Founder at CánCare – Advanced Specialty in Oncology, shared a post on X about a paper by Sophie M. Ernst et al. published in the Nature Reviews Clinical Oncology:
“Using ctDNA to track resistance in metastatic NSCLC.
Despite advances in targeted therapy, acquired resistance remains a challenge. ctDNA offers a minimally invasive way to decode evolving mechanisms and refine treatment strategies.”
Title: Utilizing ctDNA to discover mechanisms of resistance to targeted therapies in patients with metastatic NSCLC: towards more informative trials
Authors: Sophie M. Ernst, Mihaela Aldea, Jan H. von der Thüsen, Adrianus J. de Langen, Egbert F. Smit, Marthe S. Paats, Joachim G. J. V. Aerts, Laura Mezquita, Sanjay Popat, Benjamin Besse, Jordi Remon, Christian Rolfo, Hendrikus J. Dubbink, Anne-Marie C. Dingemans
You can read the Full Article in the Nature Reviews Clinical Oncology.
More posts featuring Diego Díaz García on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023